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Objectives. We sought to determine the effects of nicotine patch
therapy, when used to promote smoking cessation, on myocardial
ischemia in patients with coronary artery disease.
Background. Nicotine patches substantially increase quit rates
among cigarette smokers, but their safety in patients with myo-
cardial ischemia who are attempting to quit smoking is unknown.
Methods. This is a prospective study using exercise thallium-
201 single-photon emission computed tomography (SPECT) to
assess serial changes in the total and ischemic myocardial perfu-
sion defect size at baseline while patients were smoking and
during treatment with 14- and 21-mg nicotine patches. Entry
criteria required that patients 1) smoked >21 pack of cigarettes
per day; 2) had known coronary artery disease; and 3) had
myocardial ischemia (i.e., >25% reversible perfusion defect) on
SPECT. All patients performed symptom-limited treadmill exer-
cise, and the baseline SPECT study served as its own control. We
interpreted and computer quantified the SPECT images with no
knowledge of the testing sequence.
Results. Thirty-six of the 40 enrolled patients had exercise
SPECT at baseline and during treatment with at least 14-mg
nicotine patches. These patients had an initial perfusion defect
size of 17.5 6 10.6% while smoking an average of 31 6 11
cigarettes per day for 40 6 12 years. A significant reduction in the
total perfusion defect size (p < 0.001) was observed from baseline
(17.5 6 10.6%) to treatment with 14-mg (12.6 6 10.1%) and 21-mg
(11.8 6 9.9%) nicotine patches. This reduction occurred despite
an increase in treadmill exercise duration (p < 0.05) and higher
serum nicotine levels (p < 0.001). There was a significant corre-
lation between the reduction in defect size and exhaled carbon
monoxide levels (p < 0.001) because patients reduced their
smoking by ;74% during the trial.
Conclusions. Nicotine patches, when used to promote smoking
cessation, significantly reduce the extent of exercise-induced myo-
cardial ischemia as assessed by exercise thallium-201 SPECT.
(J Am Coll Cardiol 1997;30:125–30)
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The long-term cardiovascular health risks associated with
cigarette smoking are well established, particularly with regard
to the development of coronary artery disease and myocardial
infarction (1). For this reason, smoking cessation is clearly
desirable but often difficult to achieve owing to nicotine
addiction (2). Although patients who use nicotine patches have
over twice the long-term success rate for stopping smoking
compared with those who receive placebo (3), there is still
much concern by physicians regarding nicotine treatment in
patients with coronary artery disease. Much of the concern
stems from a few case reports in 1992 of acute myocardial
infarction in men who were using nicotine patches while
continuing to smoke cigarettes (4). In 1992, a Food and Drug
Administration Advisory Committee reviewed these cases and
concluded that the occurrence rate of myocardial infarction
was no greater than that expected for a population of middle-
aged smokers (5). However, many physicians and patients
remain skeptical, because the safety of nicotine patches in
smokers who have coronary artery disease and ischemia is not
yet known. Of particular concern is that patients may continue
to smoke while using nicotine patches, which can result in
higher plasma levels of nicotine than smoking alone. Nicotine
activates the sympathetic nervous system, which generally
increases heart rate and blood pressure, and may also induce
coronary vasoconstriction (6). This interplay of effects may
lead to diminished myocardial blood flow at times of height-
ened demand. Thus, patients with occult coronary artery
disease could potentially develop worsening manifestations of
myocardial ischemia when given nicotine patches.
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The purpose of this pilot investigation was to determine
whether nicotine patch therapy, when used to promote smok-
ing cessation, could affect the extent of exercise-induced
myocardial ischemia in patients with coronary artery disease.
Exercise thallium-201 single-photon emission computed to-
mography (SPECT) was used to assess sequential changes in
myocardial ischemia within the same patients before and after
initiation of nicotine therapy. We chose SPECT for this study
because it affords an accurate quantitative assessment of left
ventricular ischemia (7,8), which is directly related to the risk
of subsequent cardiac events (9–11).
Methods
Patients. The study group consisted of 40 patients (35 men
and 5 women, mean [6 SD] age 55 6 10 years) who 1) had
coronary artery disease on angiography; 2) smoked $1 pack of
cigarettes per day but had a strong desire to quit; and 3) had a
qualifying abnormal SPECT ($5% exercise-induced reversible
perfusion defect). Patients were excluded if they had unstable
angina, recent (,3 months) coronary angioplasty or bypass
surgery, significant valvular heart disease or intolerance to
nicotine preparations.
Study design. This was a single-center, longitudinal pilot
study evaluating the effects of nicotine patch therapy in
smoking cessation on exercise-induced myocardial ischemia.
The study protocol was approved by the institutional review
boards of both The Methodist Hospital and Baylor College of
Medicine, and all patients gave written informed consent.
Patients meeting the entry criteria were evaluated in the
outpatient clinic and were weaned off antianginal medications,
including nitrates, beta-blockers and calcium antagonists. In
hypertensive patients, angiotensin-converting enzyme inhibi-
tors were substituted for beta-blockers and calcium antagonists
for blood pressure control. Patients were allowed to take
sublingual nitroglycerin if needed for chest pain. After initial
evaluation, a baseline symptom-limited treadmill exercise test
was performed using the Bruce or modified Bruce protocol,
followed by thallium-201 SPECT.
Patients who had a reversible perfusion defect $5% were
started on 14-mg nicotine patches (Nicoderm) and encouraged
to stop smoking. The patches were applied at the same time
each morning and maintained for a 24-h period. After a
minimum of 3 days (mean 8.6 6 4.3), exercise SPECT was
repeated. Patients were then given 21-mg nicotine patches to
be worn for 24 h for a minimum of 3 days (mean 7.6 6 2.5),
followed by a third exercise SPECT. Patients performed
symptom-limited exercise using the same treadmill protocol on
the second and third exercise tests as on the baseline study.
Before each exercise test, exhaled carbon monoxide levels
were determined and serum nicotine and cotinine levels were
drawn for subsequent analysis. Expired carbon monoxide
levels were determined using the Bedfont Micro Smokelyzer
and expressed in ppm. The frozen plasma samples were sent to
Wisconsin Analytical and Research Services, where they were
analyzed for nicotine and cotinine using gas liquid chromatog-
raphy (12).
Treadmill exercise test and stress electrocardiogram. Rest
heart rate, blood pressure and a 12-lead electrocardiogram
(ECG) were recorded before treadmill exercise and at 1-min
intervals during exercise with constant monitoring of leads II,
V5 and V6. The patients were queried as to the presence of
chest pain throughout the exercise test. Electrocardiographic
ischemia was defined as $1 mm ST segment depression during
exercise.
Single-photon emission computed tomography. Thallium-
201 SPECT was performed by the method previously reported
from our laboratory (7,9,13,14). At peak exercise, 3 mCi of
thallium-201 was injected intravenously and flushed with saline
solution. Images were acquired using a large field-of-view,
single-crystal, rotating gamma camera (ADAC ARC 3000/
3300) equipped with a high resolution, parallel-hole collima-
tor. Image acquisition was performed over a 180° anterior arc
at 6° intervals and for 40 s per image. Imaging commenced
5 min after completion of the exercise test and was repeated
4 h later.
Computer quantification of tomographic images. Our
method of SPECT quantification has been previously de-
scribed in great detail (7,9). The stress and redistribution
SPECT images were computer quantified and displayed as
polar maps by one experienced investigator (J.J.M.) who had
no knowledge of the time sequence of the three SPECT studies
per patient or the carbon monoxide, nicotine and cotinine
results. The raw data polar maps for each patient were
statistically compared with those in an exercise normal data
bank consisting of 150 patients with a low (,5%) likelihood of
coronary artery disease to determine the total left ventricular
perfusion defect size (PDS) and the extent of scintigraphic scar
and ischemia. The intraobserver and interobserver reproduc-
ibility of our method for quantifying perfusion defects is
excellent, with correlation coefficients of 0.98 and 0.97, respec-
tively (15). Furthermore, based on a previous study evaluating
the reproducibility of sequential SPECT imaging, a $9%
absolute change in PDS defines the 95% confidence limit for a
reliable change beyond the variability of the technique (14).
Statistical analysis. The primary end point of this study
was the group mean absolute percent change in the total PDS
from baseline compared with during treatment with 14- and
21-mg nicotine patches. Based on our previous study describ-
ing the reproducibility of exercise SPECT (14), a sample size of
40 patients had 80% power to detect a 4% absolute percent
change in PDS from baseline. Secondary analysis included the
effects of smoking cessation and nicotine patches on ischemic
PDS, the duration of treadmill exercise and rest/exercise
hemodynamic variables.
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
PDS 5 perfusion defect size
SPECT 5 single-photon emission computed tomography (tomographic)
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Differences in mean scintigraphic, treadmill, carbon mon-
oxide, nicotine and cotinine values from baseline to 14- and
21-mg patch therapy were assessed by repeated measures
analysis of variance. This was used to avoid the multiple
comparisons issue that arises when pairwise comparisons are
made across time points. In this regard, one hypothesis test
(and one p value) was generated for each dependent variable.
However, because alpha error accumulates across each depen-
dent variable, a multiple comparison adjustment was executed
using the Bonferroni approach. A t test was used to compare
nicotine, cotinine and carbon monoxide levels between pa-
tients who either did or did not have a $9% decrease in their
total PDS. Multiple linear regression analysis determined the
relation between changes in PDS and observed changes in
carbon monoxide, nicotine and cotinine levels, as well as
specific exercise variables. All data are presented as mean
value 6 SD. A p value ,0.05 was considered significant.
Results
A total of 40 patients signed informed consent and entered
the trial. Of these, 36 completed at least two SPECT studies
(baseline and 14-mg nicotine patch), and so were considered
evaluable for the primary end point. The reasons for the
remaining dropouts will be described later.
The baseline characteristics of the study group are shown in
Table 1. Most patients were male, had significant risk factors
for coronary artery disease and were taking anti-ischemic
medications before enrollment. Virtually all patients had a
history of exertional angina. The patients enrolled smoked for
40 6 12 years, and the mean number of cigarettes currently
smoked per day was 31 6 11.
Treadmill exercise test results (Table 2). The rest heart
rate and blood pressure were similar at baseline and during
treatment with nicotine patches. Patients also had no signifi-
cant change in any of their treadmill exercise hemodynamic
variables from baseline to 14- and 21-mg patch therapy.
Fourteen patients had exercise-induced ST segment depres-
sion during the baseline exercise test. In these patients, the
time to 1 mm ST segment depression significantly increased
from 352 6 132 s at baseline to 436 6 121 s on 14-mg and
417 6 133 s on 21-mg patches (p , 0.01). Four patients (29%)
had resolution of their ST segment depression after the
baseline study. Exercise duration evaluated in all patients
significantly increased from baseline values (Table 2).
Group scintigraphic variables (Table 3). A significant re-
duction in the total exercise-induced PDS (p , 0.001) was
observed from baseline (17.5 6 10.6%) to treatment with
14-mg (12.6 6 10.1%) and 21-mg (11.8 6 9.9%) nicotine
patches. The reduction in PDS was associated with a significant
reduction in the number of cigarettes smoked per day (p ,
0.001) and exhaled carbon monoxide levels (p , 0.001). This
improvement in myocardial perfusion occurred despite signif-
icant increases in treadmill exercise duration (Table 2) and
nicotine and cotinine blood levels from baseline to 14- and
21-mg nicotine patches (Table 3). The benefits of smoking
cessation on myocardial perfusion were largely observed within
the first week of patch therapy (baseline to 14-mg patch) with
a minimal further reduction in the PDS while the subjects were
on 21-mg nicotine patches.
Individual scintigraphic results (Fig. 1). Based on our
previous results with sequential exercise SPECT (14), a $9%
temporal change in total PDS occurs in only 5% of patients by
chance alone. This is the threshold for describing a significant
change in PDS in an individual patient. Thus, only one or two
of the 36 patients in the present study should have had this
magnitude of change. Yet, 11 (31%) of the 36 patients had a
$9% decrease in their total PDS from baseline to 14-mg patch
therapy and 10 (29%) of 34 patients from baseline to 21-mg
patch therapy (Fig. 1). No patient had a $9% increase in PDS
from baseline values. Patients whose defects decreased by
$9% had a significantly greater reduction in carbon monoxide
levels (213.7 6 8.3 vs. 27.6 6 7.1 ppm, p 5 0.031) and a lesser
increase in serum nicotine levels (3.1 6 10.8 vs. 11.2 6 11.8
ng/ml, p 5 0.06) compared with those who did not show an
improvement. This result is not unexpected, because changes
in nicotine levels after patch application were predominantly
determined by reductions in cigarette smoking (i.e., exhaled
carbon monoxide levels). In fact, a significant and direct
Table 1. Baseline Characteristics
Age (yr) 55 6 10
Male 32 (89%)
Female 4 (11%)
Race/ethnicity
Black 7 (19.4%)
White 26 (72.2%)
Hispanic 3 (8.4%)
Risk factors for CAD
Positive family history 29 (80.6%)
Hyperlipidemia 11 (30.6%)
Diabetes mellitus 3 (8.3%)
Hypertension 20 (55.6%)
Claudication 5 (13.9%)
History of angina 35 (97.2%)
Cardiac history
Angina (yr) 4.0 6 4.9
Prior MI (non-Q wave) 7 (19.4%)
Prior CABG 7 (19.4%)
Prior PTCA 8 (22.2%)
CCS class (angina)
I 23 (63.9%)
II 13 (36.1%)
Antianginal therapy before enrollment
Calcium antagonists 19 (52.8%)
Beta-blockers 15 (41.7%)
Nitrates 21 (58.3%)
ASA 35 (97.2%)
Smoking history
Years smoked 40 6 12
Cigarettes smoked/day 31 6 11
Data presented are mean value 6 SD or number (%) of patients. ASA 5
aspirin; CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery
disease; CCS 5 Canadian Cardiovascular Society; MI 5 myocardial infarction;
PTCA 5 percutaneous transluminal coronary angioplasty.
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relation was observed between changes in nicotine and carbon
monoxide levels over the course of the study (r 5 0.63, p ,
0.001).
Multivariate linear regression analysis (Table 4). Multi-
variate linear regression determined which variables most
influenced a change in total PDS over the time course of this
study. Numerous independent variables were assessed, includ-
ing baseline scintigraphic results, medical history information,
nicotine and cotinine levels and the number of cigarettes
smoked per day. The baseline PDS and the final carbon
monoxide level were the only two variables that significantly
influenced the final defect size. Patients with initially large
perfusion defects had the greatest opportunity for change, and
this occurred predominantly in patients who had the largest
reductions in carbon monoxide levels. Based on regression
analysis, 76% of the observed changes in PDS could be
explained by the initial defect size and the serial change in
carbon monoxide level (r 5 0.87, p 5 0.0013). Nicotine and
cotinine plasma levels did not appear to temporally alter PDS.
Clinical outcome. Four of the 40 enrolled patients with-
drew from the study after the baseline exercise test. Two more
patients completed only the 14-mg nicotine patch phase but
were included in the analysis. The four patients who withdrew
did so for a variety of reasons: one patient discontinued for
job-related personal reasons; another had a back injury the day
after enrollment and was unable to ambulate; a third patient
had angina before and after nicotine patch therapy and was
referred for elective coronary artery bypass graft surgery; and
the last patient had an acute myocardial infarction the morning
after his baseline exercise test before starting nicotine patch
therapy.
The two patients who did not complete the study protocol
had nausea and vomiting on nicotine patches. In one patient,
symptoms quickly resolved after stopping 21-mg patches. The
other patient had nausea on the 14-mg patch, which was
Table 2. Treadmill Exercise Variables
Baseline
(n 5 36)
Nicotine Patch
p
Value
14 mg
(n 5 36)
21 mg
(n 5 34)
Rest
HR (beats/min) 79 6 15 79 6 14 79 6 15 NS
SBP (mm Hg) 137 6 19 136 6 18 140 6 18 NS
DBP (mm Hg) 81 6 11 83 6 12 85 6 9 NS
RPP (HRzSBP) 10,782 6 2,145 10,580 6 1,971 10,998 6 2,106 NS
Exercise
HR (beats/min) 141 6 16 141 6 17 142 6 18 NS
% target HR 86 6 8 86 6 9 86 6 10 NS
SBP (mm Hg) 187 6 25 184 6 24 184 6 19 NS
DBP (mm Hg) 86 6 14 87 6 22 89 6 22 NS
RPP (HRzSBP) 26,462 6 5,243 25,929 6 4,787 26,282 6 5,025 NS
Exercise duration (s) 452 6 123 472 6 116 493 6 108 0.014
Time to 1-mm ST segment depression (s)
(n 5 14)
352 6 132 436 6 121 417 6 133 ,0.01
Data presented are mean value 6 SD. DBP 5 diastolic blood pressure; HR 5 heart rate; RPP 5 rate–pressure
product; SBP 5 systolic blood pressure.
Table 3. Scintigraphic and Smoking Variables
Baseline
(n 5 36)
Nicotine Patch
p
Value
14 mg
(n 5 36)
21 mg
(n 5 34)
Perfusion defect size
(%LV)
Total 17.5 6 10.6 12.6 6 10.1 11.8 6 9.9 ,0.001
Ischemia 10.1 6 8.5 7.2 6 6.7 6.7 6 6.3 0.036
Carbon monoxide
(ppm)
23.3 6 10.5 13.8 6 9.6 12.4 6 8.8 ,0.001
Nicotine (ng/ml) 15.8 6 8.3 24.2 6 12.0 30.4 6 10.8 ,0.001
Cotinine (ng/ml) 290 6 137 338 6 186 422 6 224 ,0.002
Cigarettes smoked/
day
31 6 11 11 6 10 8 6 7 ,0.001
Data presented are mean value 6 SD. LV 5 left ventricle.
Figure 1. Mean and individual patient changes in exercise-induced left
ventricular (LV) perfusion defects from baseline to 14- and 21-mg
nicotine patch therapy. Bold lines 5 patients whose perfusion defect
size changed by $9% (beyond technique variability).
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exacerbated by excessive alcohol consumption. His symptoms
resolved while he was maintained on patch therapy. Both
patients later developed worsening angina and were referred
for bypass surgery. The latter patient continued on 21-mg
patches until the day of the operation. Of note, both patients
had large ischemic perfusion defects on their baseline exercise
SPECT (35% and 37%, respectively).
The most common side effects with nicotine patches were
skin irritation at the patch site (n 5 12), nervousness and
insomnia (n 5 5) and altered taste (n 5 5). Ten (28%) of the
36 patients had no side effects on either the 14- or 21-mg
patches. Sixteen (44%) of the 36 patients smoked #5 cigarettes
per day by the end of the study and 19% stopped smoking
entirely.
Discussion
Nicotine patch therapy significantly improves quit rates
among motivated patients who want to stop smoking (2,3).
However, legitimate concerns exist regarding the potential
adverse cardiovascular effects of nicotine substitute therapy,
particularly in patients with coronary artery disease (2,6). This
study demonstrates that nicotine patches, when used to pro-
mote smoking cessation, significantly reduce the extent of
exercise-induced myocardial ischemia despite higher plasma
nicotine levels. These scintigraphic findings are strengthened
by the concomitant increased time to exercise-induced ECG
ischemia after patch application and smoking cessation. In this
regard, nicotine does not appear to pose significant safety
concerns for patients who are attempting to quit smoking. The
long-term adverse cardiovascular effects of cigarette smoking
are well described (1). This study further suggests that carbon
monoxide and possibly other components of cigarette smoke,
rather than nicotine, may actually be more critical for the
development of myocardial ischemia.
The number of patients who had a significant reduction in
myocardial ischemia during nicotine patch therapy was partic-
ularly striking and far exceeded the known variability attribut-
able to exercise SPECT (14). Thirty-one percent of the pa-
tients in the current study had a significant reduction in
PDS—a result similar to that previously reported by our group
after anti-ischemic drug therapy in patients with stable coro-
nary artery disease (13). Furthermore, the patients with the
largest PDS at baseline had the most dramatic improvement.
Because cardiac risk is known to be directly related to the
extent of the exercise-induced PDS (9–11), the significant
reduction in defect size observed in this study would imply that
nicotine patches are safe when used for the purpose of
smoking cessation.
Possible mechanisms for observed reduction in myocardial
ischemia. This study was designed to allow examination of
several potential mechanisms for the observed changes in
exercise-induced myocardial ischemia. We prospectively col-
lected hemodynamic information on each treadmill test and
measured serial carbon monoxide, nicotine and cotinine levels.
The reduction in PDS was associated with a significant reduc-
tion in exhaled carbon monoxide, as demonstrated by multiple
linear regression analysis. The results of this investigation,
focusing on the quantitative aspects of myocardial ischemia,
are consistent with earlier studies demonstrating that increas-
ing levels of carboxyhemoglobin exacerbate treadmill exercise-
induced ST segment changes in patients with coronary artery
disease (16,17). Although our results implicate carbon monox-
ide, other components of cigarette smoke might also induce
myocardial ischemia due to effects on the coronary vasculature
or at the cellular level.
The effects of nicotine on coronary microvascular resistance
were not directly measured in this study, but rest and exercise
hemodynamic data did not significantly change from baseline
after the use of nicotine patches, despite significant increases
in serum nicotine and cotinine levels. The lack of any distinct
hemodynamic effect from higher nicotine levels is most likely
due to nicotine tolerance (18) and may explain why myocardial
ischemia did not worsen, even in patients who continued to
smoke. Although the overall results of this study are compel-
ling, the lack of a placebo control group limits conclusions
regarding the interplay between nicotine and carbon monox-
ide, and their individual effects on myocardial ischemia. A
conservative interpretation of our results is that carbon mon-
oxide from smoking worsens myocardial ischemia to a greater
extent than nicotine.
Study limitations. This pilot study did not have the power
to detect potential adverse clinical events associated with
nicotine patch therapy. Rather, we chose to examine serial
changes in myocardial perfusion as a surrogate end point to
assess safety. The observed reduction in scintigraphic ischemia
with nicotine patches supports their safety in smoking cessa-
tion, compared with the alternative of continuing to smoke.
The scintigraphic results are strengthened by the observed
increased time to exercise-induced ST segment depression
after smoking cessation with the aid of nicotine patches. Our
results may help explain one of the findings from the Lung
Table 4. Multivariate Analysis: Determinants of Perfusion Defect
Size Reduction From Baseline to 21-mg Nicotine Patch Therapy
Variable
p
Value
Baseline perfusion defect size 0.0001
Baseline carbon monoxide level 0.91
Final carbon monoxide level 0.005
Baseline nicotine level 0.51
Baseline cotinine level 0.81
History of hypertension 0.55
History of diabetes mellitus 0.26
History of hyperlipidemia 0.17
Family history of CAD 0.11
History of COPD 0.88
History of angina 0.60
Prior MI 0.86
Cigarettes smoked/day 0.16
COPD 5 chronic obstructive pulmonary disease; other abbreviations as in
Table 1.
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Health Study, which showed a lower cardiac event rate among
patients using nicotine gum (Nicorette) who quit or decreased
smoking, compared with those who continued to smoke (19).
In other studies, smoking has been shown to be an important
trigger of myocardial ischemia during normal life activities (20)
and can acutely reduce rest regional myocardial blood flow in
patients with coronary artery disease who have exercise-
induced ischemia (21). All of these studies support our obser-
vation that a higher nicotine level from patch administration is
a safe tradeoff if it encourages patients to quit smoking.
The lack of a placebo control group might raise concern
about the validity of our results. However, the patients we
studied were clinically and scintigraphically very similar to
those who had sequential exercise SPECT in a previous
placebo-controlled trial from our laboratory (13). Based on
our data establishing the reproducibility (95% confidence
limits) of computer-derived assessments of myocardial perfu-
sion by SPECT (14), one would expect only one or two patients
in the present study to have a significant decrease in PDS, and
yet this occurred in 11 (31%) of 36 patients. Furthermore, the
5.7% absolute mean reduction in PDS from baseline to
treatment with 21-mg patches is a statistical result that has
.95% power. Therefore, although a placebo group was not
incorporated into the study design, the observed changes we
report exceed the known variability associated with sequential
thallium-201 SPECT.
Clinical implications. The present study demonstrates that
the extent of exercise-induced left ventricular ischemia is
significantly reduced in patients with coronary artery disease
who attempt to quit smoking while using nicotine patches. The
use of nicotine substitutes could have important health impli-
cations for the 3 to 5 million smokers with coronary artery
disease in the United States today who would derive both an
immediate and long-term health benefit if they were to stop
smoking.
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